Taurodeoxycholate-d₆ sodium salt  (Synonyms: 牛磺脱氧胆酸钠-d₆)

Taurodeoxycholate-d₆ sodium salt is a bile salt-related anionic detergent. Taurodeoxycholate-d₆ sodium salt is formed in the liver by conjugation of deoxycholate with Taurine (HY-B0351). Taurodeoxycholate-d₆ sodium salt is used for isolation of membrane proteins including inner mitochondrial membrane proteins. Taurodeoxycholate-d₆ (TDCA) exhibits anti-inflammatory and neuroprotective effects^{[1][2][3][9][10]}.

Taurodeoxycholate-d₆ sodium salt (Taurodeoxycholic acid form) 通过荧光素酶检测，对 CHO 细胞中表达的人 TGR5 具有激动活性，EC₅₀ 为 0.79 μM^[4]。
Taurodeoxycholate-d₆ sodium salt (Taurodeoxycholic acid form, 16 h) 对在 HEK293 细胞中表达的野生型和 Y89A 突变型人 TGR5 具有激动剂活性，其 EC₅₀ 分别为 0.68 和 8.9 μM (以细胞内 cAMP 水平的升高来评估)^[5]。
Taurodeoxycholate-d₆ sodium salt (Taurodeoxycholic acid form, 50-100 μM，4 h) 增加原代人肝细胞中寡核体 DNA 切割和细胞核凋亡^[6]。
Taurodeoxycholate-d₆ sodium salt (Taurodeoxycholic acid form, 400 μM，18-24 h) 在人肝来源的 Huh7 细胞中增加 DNA 碎片和 PARP 切割，诱导凋亡^[7]。
Taurodeoxycholate-d₆ (0.05-1.00 mM，1-6 天) sodium salt 刺激肠上皮细胞增殖^[8]。
Taurodeoxycholate-d₆ (0.05-1.00 mM，24 h) sodium salt 诱导细胞周期的S期浓度显著增加和 G1 期浓度显著降低，增加c-myc IEC-6细胞蛋白和 mRNA 的表达^[8]。
Taurodeoxycholate-d₆ (25-400 ng/mL，稀释四倍，3 h) sodium salt 通过激活 cAMP-PKA 轴，抑制脂多糖激活的骨髓源性巨噬细胞 (BMDMs) 中 NF-κB 的活化^[9]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Taurodeoxycholate-d₆ (1.25-5 mg/kg，口服，6 天) sodium salt 可改善右旋糖酐硫酸钠 (DSS) 诱导的小鼠结肠炎^[9]。
Taurodeoxycholate-d₆ sodium salt (Taurodeoxycholic acid form，50 mg/kg，腹腔注射，每天 1 次，共 34 天) 预防亨廷顿舞蹈病 (HD) 大鼠模型的神经病理和相关的行为缺陷^[10]。
Taurodeoxycholate-d₆ sodium salt (Taurodeoxycholic acid form，500 mg/kg，皮下注射，每 3 天 1 次，共 7 周) 导致 R6/2 转基因 HD 小鼠纹状体神经病理的显著降低^[11]。
Taurodeoxycholate-d₆ (0.5 mg/kg，静脉注射，一次) sodium salt 对患有脓毒症的 C57BL/6N 小鼠提供保护，但不能保护患有脓毒症的 TGR5 KO 小鼠^[12]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

528.73

牛磺脱氧胆酸钠-d₆

C₂₆H₃₉D₆NNaO₆S

2687960-92-3

1180-95-6

固体

White to off-white

牛磺脱氧胆酸钠-d₆

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Villavicencio-Queijeiro A, et al. The fully-active and structurally-stable form of the mitochondrial ATP synthase of Polytomella sp. is dimeric. J Bioenerg Biomembr. 2009 Feb;41(1):1-13.  [Content Brief]

  [2]. Kispal G, et al. Isolation and characterization of 3-hydroxyacyl coenzyme A dehydrogenase-binding protein from pig heart inner mitochondrial membrane. J Biol Chem. 1986 Oct 25;261(30):14209-13.  [Content Brief]

  [3]. Choi HJ, et al. Evaluation of acute and subacute toxicity of sodium Taurodeoxycholate in rats. Drug Chem Toxicol. 2021 May;44(3):268-276.  [Content Brief]

  [4]. Sato H, et al. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem. 2008 Mar 27;51(6):1831-41.  [Content Brief]

  [5]. Gertzen CG, et al. Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists. Eur J Med Chem. 2015 Nov 2;104:57-72.  [Content Brief]

  [6]. Benz C, et al. Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes. Eur J Clin Invest. 2000 Mar;30(3):203-9.  [Content Brief]

  [7]. Xie Q, et al. Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation. Hepatology. 2002 Sep;36(3):592-601.  [Content Brief]

  [8]. Yamaguchi J, et al. Taurodeoxycholate increases intestinal epithelial cell proliferation through c-myc expression. Surgery. 2004 Feb;135(2):215-21.  [Content Brief]

  [9]. Zou Y, et al. Taurodeoxycholate ameliorates DSS-induced colitis in mice. Int Immunopharmacol. 2023 Sep;122:110628.  [Content Brief]

  [10]. Keene CD, et al. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Exp Neurol. 2001 Oct;171(2):351-60.  [Content Brief]

  [11]. Keene CD, et al. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10671-6.  [Content Brief]

  [12]. Chang S, et al. Taurodeoxycholate Increases the Number of Myeloid-Derived Suppressor Cells That Ameliorate Sepsis in Mice. Front Immunol. 2018 Sep 18;9:1984.  [Content Brief]